CRISPR Therapeutics (NASDAQ: CRSP) CFO covers RSU taxes with share sale and gift
Rhea-AI Filing Summary
CRISPR Therapeutics AG Chief Financial Officer Prasad Raju exercised and vested restricted stock units and related common shares, then disposed of a portion mainly for tax obligations and a gift. On March 14, 2026, he acquired 16,875 common shares through the conversion of restricted stock units granted in 2023 and 2025. On March 16, 2026, 9,869 common shares were sold at $48.26 per share to satisfy tax withholding requirements under the company’s RSU Settlement Policy, and 750 shares were transferred as a bona fide gift without consideration. After these transactions, he directly held 13,023 common shares, which remain subject to a lock-up related to the company’s convertible senior notes due 2031.
Positive
- None.
Negative
- None.
Insights
Routine RSU vesting with tax sales and a gift; limited signal.
The transactions show CRISPR Therapeutics CFO Prasad Raju converting restricted stock units into 16,875 common shares, consistent with multi-year vesting schedules from awards granted in 2023 and 2025. This is standard equity compensation, not an open-market purchase.
On March 16, 2026, 9,869 common shares were sold at $48.26 per share. Footnote language explains these sales were mandated to cover tax withholding obligations under the company’s RSU Settlement Policy, rather than discretionary trading. A further 750 shares were transferred as a bona fide gift with no consideration.
Following these moves, Raju directly holds 13,023 common shares, which remain subject to a lock-up tied to convertible senior notes due 2031. Because the dispositions are largely tax- and gift-related, with no remaining derivative position reported, the overall signal for investors is routine and not thesis-changing.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Shares | 5,848 | $48.26 | $282K |
| Sale | Common Shares | 4,021 | $48.26 | $194K |
| Gift | Common Shares | 750 | $0.00 | -- |
| Exercise | Restricted Stock Units | 10,000 | $0.00 | -- |
| Exercise | Restricted Stock Units | 6,875 | $0.00 | -- |
| Exercise | Common Shares | 10,000 | $0.00 | -- |
| Exercise | Common Shares | 6,875 | $0.00 | -- |
Footnotes (1)
- These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Reporting person remains subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031. Transfers of lock-up securities as a bona fide gift are permitted. No consideration was received by the reporting person in connection with such transfer. This restricted stock unit award was granted on March 14, 2023 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on March 14, 2024, (ii) one quarter of the shares vesting on March 14, 2025, (iii) one quarter of the shares vesting on March 14, 2026, and (iv) one quarter of the shares vesting on March 14, 2027. This restricted stock unit award was granted on March 14, 2025 with respect to 27,500 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029.
